FASEB SRC on Melatonin Receptors: Actions and Therapeutics

描述(申请人提供)：2011年的会议将集中讨论褪黑素受体在抑郁症、自闭症谱系障碍、药物诱导的行为敏感化、神经退行性疾病、失眠、代谢障碍、心血管疾病、癌症、炎症障碍和免疫改变中作为潜在治疗靶点的作用。在过去的12年里，褪黑素配体的分子和药理作用方面取得了很大的进展。此外，作用于MT1和MT2受体的褪黑素配体已被用于治疗失眠、昼夜节律紊乱和抑郁症(Rozerem，武田制药北美，美国；Valdoxan，Servier，法国，欧洲)。用于治疗这些疾病的其他褪黑激素激动剂目前正在开发中。我们2008年的会议非常成功地将世界各地在褪黑素受体领域工作的科学家聚集在一起，介绍和讨论他们的新发现；我们认为，又到了将褪黑素受体专家聚集在一起讨论这一迅速扩大的领域自2008年以来的最新进展的时候了，并为未来的研究确定了新的方向。会议的主要重点将是确定和讨论以褪黑素受体为靶点的各种疾病状态(特别是中枢神经系统)的新治疗方法。提出和讨论的数据范围从褪黑素的生理作用的鉴定到受体蛋白的结构和功能以及它们作为治疗靶点的作用。这是唯一一次将使用褪黑素受体作为治疗药物开发靶点的研究人员聚集在一起的会议。自2008年会议以来，许多具有潜在治疗益处的褪黑素的新的和多样化的作用被发现，这引起了生物医学科学家和临床医生的极大兴趣。 与公共健康相关：这次会议将第二次汇集世界上最顶尖的褪黑素专家，介绍和讨论褪黑素受体的生理学和药理学，褪黑素的作用，以及新的治疗性褪黑素配体。在可预见的将来，随着更多的新的褪黑素配体进入市场，使用褪黑激素配体的治疗策略的进展将大大增加。这将对治疗和预防一系列疾病产生重大而独特的影响，包括失眠和其他睡眠障碍、昼夜节律紊乱、神经系统疾病、抑郁症、癌症、免疫紊乱、代谢紊乱和肥胖、心血管问题、炎症、神经退行性疾病和骨质疏松症。

DESCRIPTION (provided by applicant): The 2011 conference will focus on the role of melatonin receptors as potential therapeutic targets in depression, autism spectrum disorders, drug-induced behavioral sensitization, neurodegenerative diseases, insomnia, metabolic disorders, cardiovascular disorders, cancer, inflammatory disorders and altered immunity. Over the past 12 years, great advances have been achieved in the molecular and pharmacological actions of melatonin ligands. Furthermore, melatonin ligands acting on MT1 and MT2 receptors have been marketed for the treatment of insomnia, circadian disorders and depression (Rozerem, Takeda Pharmaceuticals North America, USA; Valdoxan, SERVIER, France, Europe). Other melatonin agonists for treatment of these disorders are currently in development. Our 2008 conference was highly successful at bringing together scientists from around the world working in the melatonin receptor area to present and discuss their new findings; we believe it is again time to bring melatonin receptor experts together to discuss the most recent advances since 2008 in this rapidly expanding field as well as to establish new directions for future research. The main emphasis of the conference will be on identifying and discussing novel therapeutic approaches for a variety of disease states (special emphasis on the CNS) using melatonin receptors as targets. The data presented and discussed will range from the identification of melatonin's physiological role to the structure and function of the receptor proteins and their role as therapeutic targets. This is the only conference that brings together investigators using melatonin receptors as targets for the development of therapeutic agents. Many new and diverse actions of melatonin with potential therapeutic benefits have been discovered since the 2008 conference that are of great interest to biomedical scientists and clinicians. PUBLIC HEALTH RELEVANCE: This conference will bring together, for only the second time, a group of the world's foremost melatonin experts to present and discuss the physiology and pharmacology of melatonin receptors, the actions of melatonin, and new therapeutic melatonin ligands. In the foreseeable future, advances in therapeutic strategies using melatonin ligands will substantially increase as additional new melatonin ligands with efficacy at the level of melatonin receptors reach the market. This will have a significant and unique impact on the treatment and prevention of a wide range of diseases, including insomnia and other sleep disorders, circadian rhythm disturbances, neurological diseases, depression, cancer, immunological disorders, metabolic disorders and obesity, cardiovascular problems, inflammation, neurodegenerative disorders, and osteporosis.